Ford’s Louisville Assembly Plant Will Be Down Again Next Week As Co. Continues To Deal With Software Issue On Escape
- Automotive News Reporter Tweet
Numinus Debuts 3rd Research Site In US, Touts Faster Services & More Participants
Numinus Wellness (OTCQX: NUMIF) expanded its clinical research capabilities into Phoenix, where the psychedelic-assisted therapy provider currently operates mental health clinics.
Amarin Urges Shareholders To Vote “Against” Sarissa’s Harmful Proposals At Upcoming General Meeting Says ‘It Has No Plan, No New Ideas And An Underqualified Slate’
The NEW Amarin and NEW Board is On the Right Track – Leading Independent Experts, ISS and Glass Lewis, Agree that Sarissa Representation is Not Warranted
Sarissa's Misguided Campaign to Remove
Cass Information Systems, Inc. Elects Martin Resch As President And Chief Executive Officer; Eric Brunngraber Named Executive Chairman
Cass Information Systems, Inc. (NASDAQ:CASS), the leading provider of transportation, energy, telecom, and waste invoice payment and information services, announced that Martin Resch, President and Chief
East Palestine Community Update On Environmental Monitoring, Assistance For Feb. 16; Distributing Over $1.7M In Direct Financial Assistance To More Than 1,100 Families; Establishing A $1M Fund Available Immediately To The Community
Norfolk Southern Corporation (NYSE:NSC) today provided an update on environmental monitoring and community assistance for the Village of East Palestine, Ohio. To date, Norfolk Southern has:
Completed nearly 500
View To Seek Stockholder Approval Of Reverse Stock Split As Part Of Nasdaq Compliance Plan
View, Inc. (NASDAQ:VIEW) ("View") today announced that it plans to hold a special meeting of stockholders to seek approval of a reverse stock split of View's Class A Common Stock, in order to regain
Delix Inks Deal With Cellectricon; Psyched Wellness Partners With Spacestation
Delix Nabs 2 New Partners
Neuroscience company Delix Therapeutics is partnering with Sweden-based Cellectricon and New York-based Expressive Neuroscience.
The goal is to expedite Delix's drug development pipeline.
Algernon Touts Positive Study Findings, Confirms Next Trial Phase With Escalated Dose
Algernon Pharmaceuticals (OTCQB: AGNPF)’s subsidiary Algernon NeuroScience has completed the first cohort in its Phase 1 clinical study of
Novel Ketamine Topical Cream To Treat PTSD Gets First In-Human Trials
Psycheceutical Bioscience (OTCPK: BWVI) is advancing its proprietary ketamine topical formulation into clinical studies.
The life sciences company has partnered with Australian-based contract research organization iNGENū Pty Ltd.